Evidence map›Paper›PMID 40407127›Full record

ArticleCancer research communications2025

Dual Role of NRF2 in Pancreatic Precursor Lesions.

Shu Ichimiya, Sung Shin Ahn, Maya S Dixon, John P O'Sullivan, Lela C DeVine, Alex Chen, Takeo Yamamoto, Yoshinao Oda, Masafumi Nakamura, Iok In Christine Chio

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shu IchimiyaDepartment of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-8184-615X
Sung Shin Ahn *Department of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-1236-2143
Maya S Dixon *Department of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0009-0004-6093-2675
John P O'SullivanDepartment of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0009-0006-7938-5629
Lela C DeVineDepartment of Biology, Barnard College, New York, New York.ORCID 0000-0001-9809-9501
Alex ChenDepartment of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0009-0001-3653-3023
Takeo YamamotoDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0009-0006-2188-314X
Yoshinao OdaDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-9636-1182
Masafumi NakamuraDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-6196-8643
Iok In Christine ChioDepartment of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-3635-2679

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Studying the role of eIF4A in Pancreatic CancerR01CA267870 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Christine Iok In Chio · 2022 to 2026
$2.3M
Characterizing the role of MSRA in pancreatic tumorigenesisR01CA273023 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Christine Iok In Chio · 2023 to 2026
$1.8M
NRF2-dependent redox signaling in pancreatic cancerR01CA240654 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHIO, CHRISTINE IOK IN · 2020 to 2024
$1.8M
NCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA240654NCI NIH HHS R01 CA267870NCI NIH HHS R01 CA273023
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) arises from distinct precursor lesions, primarily pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). Unlike PanIN, IPMN is a cystic lesion detectable by imaging, providing an opportunity for early intervention. However, the molecular determinants guiding the formation of PanIN versus IPMN remain poorly understood. In this study, we uncover a previously unrecognized role for nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of redox homeostasis, in dictating pancreatic precursor lesion fate. Although NRF2 is known to promote PanIN formation and sustain PDA, we found that active NRF2 levels are significantly lower in human IPMN compared with PanIN and PDA. Using a conditional NRF2 knockout mouse model, we demonstrate that NRF2 loss significantly increases IPMN-like cystic tumor formation in KRASG12D-mutant pancreatic epithelium, revealing an unexpected suppressive role of NRF2 in IPMN development. Mechanistically, NRF2 suppresses IPMN formation through redox-independent transcriptional repression of SAM pointed domain-containing Ets transcription factor and MUC6, key markers of IPMN. These findings establish NRF2 as a lesion-specific regulator of pancreatic tumorigenesis, providing new molecular insights into PDA progression and potential biomarkers for early detection and risk stratification. SIGNIFICANCE: This study reveals a context-dependent role of NRF2 in pancreatic tumorigenesis, promoting PanIN progression while suppressing IPMN formation. These findings provide new insights into early lesion heterogeneity and highlight NRF2 status as a potential biomarker for risk stratification in pancreatic cancer.

Indexed as

Carcinoma in SituCarcinoma, Pancreatic DuctalNF-E2-Related Factor 2Pancreatic Intraductal NeoplasmsPancreatic NeoplasmsPrecancerous ConditionsAnimalsGene Expression Regulation, NeoplasticHumansMiceMice, KnockoutProto-Oncogene Proteins p21(ras)NFE2L2 protein, humanNfe2l2 protein, mouseNF-E2-Related Factor 2Proto-Oncogene Proteins p21(ras)

Identifiers

PMID40407127
PMCPMC12158068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.